Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH) provided an update on strategic review. As previously announced, the company initiated a robust strategic review at the end of June 2023 and is continuing to review all strategic options for the company, which include a variety of possibilities including, but not limited to, a potential sale, merger, or other strategic transaction. At this time, there are no further updates on the matter, other than that the process is continuing.

The Board of Directors and the Executive Leadership team remain committed to running a fulsome process that reflects the best interests of the Company, the company?s shareholders, and other key stakeholders, including the company?s patients, healthcare providers, and the company?s employees.